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Ganglioside mimicry in the lipopolysaccharide (LPS) fraction of Campylobacter jejuni isolated from Guillain-
Barré syndrome (GBS) and Miller Fisher syndrome (MFS) patients was compared with isolates from patients
with an uncomplicated enteritis. The antibody response to C. jejuni LPS and gangliosides in neuropathy
patients and controls was compared as well. LPS from GBS and MFS-associated isolates more frequently
contained ganglioside-like epitopes compared to control isolates. Almost all neuropathy patients showed a
strong antibody response against LPS and multiple gangliosides in contrast to enteritis patients. Isolates from
GBS patients more frequently had a GM1-like epitope than isolates from MFS patients. GQ1b-like epitopes
were present in all MFS-associated isolates and was associated with anti-GQ1b antibody reactivity and the
presence of oculomotor symptoms. These results demonstrate that the expression of ganglioside mimics is a
risk factor for the development of post-Campylobacter neuropathy. This study provides additional evidence for
the hypothesis that the LPS fraction determines the antiganglioside specificity and clinical features in post-
Campylobacter neuropathy patients.
Campylobacter jejuni infection is the most frequent trigger-
ing event in postinfectious neuropathies such as the Guillain-
Barré syndrome (GBS) and Miller Fisher syndrome (MFS)
(13, 23, 29). The exact pathogenesis of post-Campylobacter
neuropathy is unknown, but molecular mimicry between bac-
terial glycoconjugates and peripheral nerve gangliosides has
been implicated (32). Cross-reactive antibodies between C.
jejuni lipopolysaccharides (LPS) and gangliosides have been
identified in GBS and MFS patients (12, 20). The specificity of
this cross-reactive antiganglioside-LPS response is associated
with different disease profiles. Antibody reactivity against
GM1, GM1b, and GalNAc-GD1a is associated with pure mo-
tor GBS (2, 33), and anti-GQ1b antibody reactivity has a strong
association with oculomotor symptoms and ataxia (15).
Ganglioside mimics have been identified in C. jejuni LPS by
biochemical and serological methods (17) (Fig. 1). Mass spec-
tometry revealed the presence of GM1- and GD1a-like struc-
tures in LPS from GBS patients (22, 36) and GD3-like struc-
tures in MFS-associated LPS (25). Serological studies with
ganglioside-binding toxins and monoclonal antiganglioside an-
tibodies confirmed these findings (26, 37). Most C. jejuni iso-
lates from GBS and MFS patients that were investigated by
biochemical and/or serological methods exhibit ganglioside
mimicry, but this may have been caused by selection bias. Little
information is available concerning the expression of ganglio-
side mimics in isolates from uncomplicated C. jejuni enteritis
patients compared to neuropathy-associated isolates (26). Fur-
thermore, detailed studies on antibody responses to glycolipid
antigens such as LPS and gangliosides in C. jejuni enteritis
patients have been limited.
The aim of the present study was to investigate whether
there is a difference in the expression of ganglioside mimics in
unrelated C. jejuni isolates from GBS and MFS patients com-
pared to C. jejuni isolates from uncomplicated enteritis pa-
tients. In addition, we studied the antibody response to LPS
and gangliosides in culture-proven Campylobacter-associated
neuropathy patients and control enteritis patients to investi-
gate host-related differences in the immune response to glyco-
lipid antigens.
MATERIALS AND METHODS
Patients and isolates. We collected 18 GBS- or MFS-related C. jejuni isolates
from patients in The Netherlands and Belgium between 1991 and 1998 (7). Two
isolates were cultured from the diarrheal stools of two family members of a GBS
patient. The GBS patient remained culture negative but showed a serological
response highly suggestive of a recent C. jejuni infection (1). Only one of these
strains was included in the analysis, leaving the total number of neuropathy
associated strains at 17. Acute-phase serum samples obtained within one week of
the onset of symptoms, clinical information on oculomotor symptoms, and ataxia
were available for 16 patients. All GBS patients fulfilled the diagnostic criteria
(4), and all MFS patients had oculomotor symptoms and ataxia in the absence of
limb weakness. Fourteen of the GBS and MFS patients had suffered a period of
diarrhea during the weeks before the development of neurological symptoms;
four patients did not report a gastrointestinal illness. Two GBS patients had
oculomotor symptoms in addition to their limb weakness. All but two neuropathy
patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a
protein extract of C. jejuni, indicative of a recent infection (9). One of the
remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a
history of diarrhea. Twenty-three control C. jejuni isolates were obtained from
patients with an uncomplicated C. jejuni enteritis without neurological symp-
toms. Of 15 of these control patients, serum samples taken in the first week of the
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disease were available. All control isolates were collected between 1990 and 1999
from sporadic enteritis patients. All control enteritis patients had suffered from
diarrhea. Based on a limited number of patients, there were no differences
between the neuropathy and the control enteritis patients with respect to the
duration of diarrhea. The seasonal distribution of neuropathy associated and
control isolates was the same with a broad summer peak. As additional controls
for serotyping of C. jejuni isolates, we used reference strains from which the core
oligosaccharides have been shown to contain a GM1 mimic (Penner O:19,
CCUG 10950) (5), a GD3 mimic (Penner O:10, CCUG 10943) (19), or no
ganglioside mimic (Penner O:3, CCUG 10937) (6) (Fig. 1).
Serology. Acute-phase serum samples were tested for IgM and IgG antibody
reactivity against asialo-GM1 (GA1), GM1, GM2, GD1a, GD1b, GD3, and
GQ1b by enzyme-linked immunosorbent assay (ELISA) and confirmed by thin-
layer chromatography as described previously (10). All glycolipids were obtained
from Sigma (St. Louis, Mo.), except GQ1b (Biocarb, Lund, Sweden). LPS frac-
tions from all isolates were isolated with the hot-phenol–water method and
processed as described previously (12). All LPS fractions showed a dense band
migrating at 8 to 15 kDa after electrophoresis on a polyacrylamide gel and silver
staining (Novex, San Diego, Calif.), indicating the presence of LPS (5). For the
detection of anti-LPS reactivity, serum samples were tested by ELISA at dilu-
tions of 1:100 and 1:1,000 as described previously (11). Samples were considered
positive when the corrected optical density value was 3 standard deviations of
the mean optical density for a group of 12 healthy controls without serological
evidence of a recent C. jejuni infection.
To assess serum samples for cross-reactive antibodies between LPS and gan-
gliosides, serum was incubated with C. jejuni LPS conjugated to Octyl-Sepharose
CL4B beads. Then, 250 g of LPS was added to 1 ml of Octyl-Sepharose CL4B
in methanol-water (1:1 [vol/vol]) containing 0.1 M KCl and mixed for 1.5 h. After
several washes with phosphate-buffered saline (pH 7.8; PBS), serum samples
were incubated with LPS-Sepharose conjugates for 5 h at 4°C. After centrifuga-
tion, absorbed serum samples were tested for anti-LPS and antiglycolipid reac-
tivity as described above. Serum samples that were incubated with beads coupled
to LPS from the Penner O:3 serostrain that does not contain a ganglioside mimic
(6) or uncoupled beads served as controls.
Serological typing of C. jejuni LPS. (i) Polyclonal serum panel. Purified LPS
was tested in an ELISA-based system for the presence of ganglioside-like
epitopes with a panel of ganglioside-reactive sera divided into four groups. Some,
but not all, of the samples were from culture-positive GBS or MFS patients. The
first group (GM1) consisted of 10 serum samples with IgG anti-GM1 reactivity.
The second group (GQ1b) consisted of 10 serum samples with IgG anti-GQ1b
reactivity. The third group (Other) consisted of four serum samples with anti-
ganglioside reactivity against GM2 and GD1a. This group was included to detect
ganglioside mimics that could not be defined with sera from the GM1 and GQ1b
group. The fourth group (HC) consisted of 12 healthy controls without serolog-
FIG. 1. Structure of C. jejuni LPS types and the corresponding ganglioside mimics. Symbols: , N-acetylgalactosamine;, galactose; E, glucose;
, sialic acid; {, (phosphoryl)ethanolamine; , N-acetylglucosamine; , heptose; o, 3-deoxy-D-manno-octulosonic acid; F, dideoxyglucose; },
2-aminoethyl phosphate.
VOL. 70, 2002 GANGLIOSIDE MIMICRY IN LPS 1203
ical evidence for a recent C. jejuni infection. An LPS was considered to have a
GM1-like epitope when at least 3 of 10 serum samples from the GM1 group had
an optical density of 3 standard deviations above the mean of the healthy
controls, with a minimum optical density of 0.300 (to avoid false-positive samples
due to the low levels of anti-LPS reactivity seen in healthy control samples). The
criteria for LPS bearing a GQ1b-like epitope were similar with the GQ1b panel
of sera. An LPS was considered to have an undefined ganglioside-like epitope,
which could not be designated GM1-like or GQ1b-like, when the LPS showed
reactivity with only one or two serum samples in either the GM1 or the GQ1b
group or reactivity with one or more serum samples from the “other” group.
(ii) Toxins, lectin, and MAbs. The specificity of the binding of cholera toxin B
subunit (CT), tetanus toxin fragment C (TT), peanut agglutinin (PNA), and the
monoclonal antiganglioside antibodies (MAbs) Sm1 (31), Wo1 (21), Ha1rbc
(30), CGM3 (8), and EG1 (8) was validated by binding these ligands to GA1,
GM1, GM2, GM3, GD1a, GD1b, GD3, GT1b, or GQ1b or to bacterial LPS.
Plates (96 well; Nunc Immunosorb, Roskilde, Denmark) were coated with gly-
colipids as described previously (11). Wells without glycolipids served as controls.
Peroxidase-conjugated CT (List Biologicals, Campbell, Calif.; Sigma), biotin-
conjugated CT (List Biologicals), peroxidase-conjugated TT (List Biologicals),
peroxidase-conjugated PNA (Sigma), or the MAbs diluted in PBS-bovine serum
albumin were added for 1 h at room temperature (toxins) or overnight at 4°C
(MAbs). After being washed with PBS, plates containing peroxidase-conjugated
ligands were developed with o-phenyldiamine. Biotin-conjugated CT was incu-
bated with peroxidase-conjugated avidin (ABC Kit; Vector, Burlingame, Calif.)
for 1 h at room temperature, followed by washing and development. Plates
containing MAbs were incubated with peroxidase-conjugated anti-human or
anti-mouse antibodies and washed with PBS before development. Specificity of
binding to purified glycolipids was confirmed with a thin-layer chromatography
overlay (14).
Statistical analysis. Statistical analysis was performed with Stata verson 6.0
(Stata, College Station, Tex.). Differences in proportions were tested with the
Fisher exact test. Binding of toxins, lectin, and MAbs was evaluated with the
Mann-Whitney U test. All tests were two-sided. A P value of 0.05 was consid-
ered significant.
RESULTS
Patient serology. All but one of the GBS and all MFS pa-
tients had IgM and/or IgG antibody reactivity against purified
C. jejuni LPS (Table 1). Most serum samples contained reac-
tivity not only against LPS from their autologous isolate but
also from other C. jejuni isolates. Of 16 neuropathy patients, 13
showed antibody reactivity to a variety of peripheral nerve
glycolipids (Table 2). All MFS patients had anti-GQ1b reac-
tivity. Two GBS patients displayed no reactivity against the
purified glycolipids, although they both had IgG anti-LPS re-
activity. Depletion experiments with LPS conjugated to Sepha-
rose beads demonstrated that the antiglycolipid and anti-LPS
antibodies were cross-reactive, not only in patients with anti-
GM1 and anti-GQ1b antibodies but also in patients with anti-
GD1a and high-titer anti-GA1 antibodies (data not shown).
Serum from neuropathy patients more frequently contained
antibody reactivity against any of the panel of purified neural
TABLE 1. Antiglycolipid titers and anti-LPS reactivity in GBS and MFS patients
Condition and patient
IgG titera IgM titera
GA1 GM1 GM2 GD1a GD1b GD3 GQ1b LPS GA1 GM1 GM2 GD1a GD1b GD3 GQ1b LPS
GBS
GB1 1,600 800       1,600 400   100   
GB2 NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
GB3                
GB4                
GB5 400  100      400       
GB11 200 800   3,200           
GB13/14 1,600 400       800 200   200   
GB15                
GB17 25,600 100    100   200       
GB18 3,200 2,800   1,600     200      
GB21 800 100  6,400            
GBS oculomotor symptoms
GB16 200     3,200 102,400  100       
GB19      100 12,800  100       
MFS
MF6     100 200 1,600         
MF7       400        200 
MF8     200 200 800      200   
MF20 1,600      100  400       
a NT, not tested; , titer 100; , titer 100.
TABLE 2. LPS structure and diagnosis of patients with C. jejuni enteritis
LPS structure
No. of patients (%) with diagnosis of: P
GBS (n  13) MFS (n  4) Enteritis (n  23) GBS or MFS vs enteritis GBS vs MFS
GM1-like 11 (85) 2 (50) 13 (57) 0.32 0.22
GQ1b-like 2 (15) 4 (100) 2 (9) 0.053 0.006a
Other ganglioside 8 (62) 4 (100) 12 (52) 0.33 0.26
No ganglioside 1 (8) 0 8 (35) 0.054 1.00
a Statistically significant.
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glycolipids or C. jejuni LPS (15 of 16) than control enteritis
patients (6 of 15) (P  0.001). In the enteritis group, only one
patient had low-titer IgG anti-GM1. Two other patients had
anti-GA1 IgG antibodies. Antibody reactivity to gangliosides
with two or more sialic acids could not be detected in any of the
enteritis patients. Anti-LPS antibodies occurred in three en-
teritis patients, and one of them also had antibody reactivity
against GA1.
Serological typing of C. jejuni isolates with GBS or MFS
patient sera. Examples of LPS reactivity with antiganglioside
antibody containing serum samples and validation of the serum
panel with LPS with a known biochemical structure are shown
in Fig. 2. The antiganglioside serum panel reacted with all but
one LPS from the GBS and MFS isolates, indicating the pres-
ence of ganglioside mimics in almost all neuropathy-associated
isolates. LPS from most isolates reacted with serum samples
from more than one group, suggesting the presence of multiple
ganglioside mimics. The Penner serotype was not related to the
expression of ganglioside-like epitopes on the LPS. The fre-
quency of GM1-like epitopes was higher in GBS-associated
isolates than in MFS or control isolates (Table 2). GQ1b-like
epitopes occurred more frequently in MFS-associated isolates
than in GBS or control isolates (P  0.006, Table 2). Of the
control enteritis isolates, 35% did not react with any of the
antiganglioside sera, indicating the absence of ganglioside
mimics in these isolates.
To investigate whether the LPS structure predicts the anti-
ganglioside specificity and clinical features in the neuropathy
patients, we correlated the results of the LPS typing with these
features. In general, the type of ganglioside mimicry in C. jejuni
LPS concurred with the antiganglioside specificity and clinical
features in the GBS and MFS patients (Table 3).
Serological typing of C. jejuni isolates with toxins, lectin,
and MAbs. All ligands reacted with purified LPS fractions.
None of the toxins, lectin, or MAbs reacted with LPS from the
Penner O:3 strain (data not shown). Validation of CT binding,
which in its unconjugated form binds highly selectively to GM1
(3), showed differential binding specificity of CT, depending on
the conjugated molecule and independent from the concentra-
tion of glycolipids (Table 4). Binding of CT and the two anti-
GA1 and anti-GM1 MAbs correlated well with the serum
panel typing system for GM1-like epitopes. CT binding showed
a clear difference between GBS- and MFS-related isolates (P
 0.03, Fig. 3A), although not all GBS-related isolates bound
CT and CT binding was not restricted to GBS patients with
anti-GM1 antibodies. In addition, the level of CT binding was
higher in neuropathy-associated isolates than in control iso-
lates (P  0.02). The antidisialosyl MAbs clearly distinguished
MFS isolates from GBS isolates (Fig. 3B). PNA and TT bind-
ing did not have additional value in distinguishing GBS from
MFS strains (data not shown).
FIG. 2. C. jejuni LPS reacts differentially with antiganglioside antisera. Purified LPSs were tested for reactivity against a panel of serum samples
containing antiganglioside reactivity against GM1 and GA1 (GM1), GQ1b and GD3 (GQ1b), or other gangliosides and/or a combination of GA1
and GQ1b (“other”). (A and B) LPS from GBS patients GB11 and GB16 reacted with sera of the GM1 group. In panel B, LPS from GBS patient
GB16, who has an overlap of GBS and MFS, reacted with the sera of the GM1, GQ1b, and “other” groups. (C) LPS from MFS patient MF8 reacted
predominantly with GQ1b sera. (D) LPS from the O:19 serostrain reacted with sera of the GM1 group but not with those of the GQ1b group,
whereas LPS from the O:10 serostrain reacted with the sera from the GQ1b group. (F) LPS from the O:3 serostrain, which does not contain a GM1-
or GQ1b-like structure, did not react with any of the sera. None of the LPS fractions reacted with sera from the healthy controls (HC). Dashed
lines indicate the cutoff values.
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DISCUSSION
The present study demonstrates that C. jejuni isolates from
GBS and MFS patients more frequently express ganglioside
mimics in their LPS than isolates from uncomplicated enteritis
patients. Cross-reactive anti-LPS–antiglycolipid responses can
be detected in almost all culture proven cases of C. jejuni-
related GBS and MFS but not in serum from patients with an
uncomplicated enteritis. Differences in LPS structure deter-
mine the specificity of the antibody response and thereby the
clinical features of the patients.
The GBS patients were highly diverse in their antiganglio-
side specificity, but almost all had antibody reactivity against
the LPS from the isolate with which they had been infected.
This serves as further evidence that the antiganglioside anti-
bodies in GBS and MFS patients result from the previous
infection with C. jejuni. The presence of strong anti-LPS anti-
body reactivity in patients without reactivity against a panel of
gangliosides indicates the presence of antibody reactivity
against unknown gangliosides. In contrast to the findings in
neuropathy patients, the response to bacterial and neural gly-
colipids was significantly lower in patients with an uncompli-
cated C. jejuni enteritis, despite the presence of ganglioside
mimics in the LPS of some enteritis isolates. This finding un-
derscores the influence of host-related factors such as poly-
morphisms in immune-response genes, in addition to bacteri-
um-related factors, in the development of neurological
symptoms after an infection with C. jejuni (18, 26). This may
either depend on differential expression of ganglioside mimics
in C. jejuni LPS, due to phase variation in genes encoding
glycosyltransferases (16), or to the influence of other immuno-
modulating factors (28).
For the present study we developed a method with serum
samples containing antiganglioside antibody reactivity to de-
tect and define ganglioside-like epitopes on C. jejuni LPS.
Serum samples containing antibody reactivity to gangliosides
other than GM1 or GQ1b reacted strongly with LPS from
several isolates, which indicates the presence of other, as-yet-
undefined ganglioside mimics. In addition, most LPS fractions
reacted with serum samples from more than one serum group,
suggesting the presence of multiple ganglioside epitopes on
one isolate (34). The data obtained by the serum panel method
were confirmed with MAbs and toxins, thus demonstrating the
validity of the method.
The lack of CT binding of all MFS-related isolates and some
GBS-related isolates is important since CT-binding assays are
currently being used to identify isolates that have a higher
potential to induce neurological symptoms (18, 24). The anti-
GA1 and anti-GM1 MAbs reacted selectively with a limited
number of GBS-related isolates. These results indicate that the
use of very specific ligands may not be sufficient to detect the
wide variety of ganglioside mimics in C. jejuni LPS. Conse-
quently, GBS patients may have antiganglioside antibodies
that are directed against GM1-like gangliosides (e.g., GM1b or
GalNAc-GD1a) (2, 35). Together, these results indicate that
TABLE 3. LPS structure, antiganglioside reactivity, and clinical features of GBS and MFS patients
Parameter
No. of patients (%) positive
for GM1-like LPS Pa
No. of patients (%) positive
for GQ1b-like LPS P a
Yes (n  12) No (n  4) Yes (n  6) No (n  10)
Antiganglioside reactivity
Anti-GA1 9 (75) 1 (25) NS* 3 (50) 7 (70) NS*
Anti-GM1 6 (50) 0 NS* 1 (17) 5 (50) NS*
Anti-GD3 4 (33) 1 (25) NS* 4 (67) 1 (10) 0.04*
Anti-GQ1b 4 (33) 2 (50) NS* 5 (83) 1 (10) 0.008*
Clinical features
Oculomotor symptoms 4 (33) 2 (50) NS† 5 (83) 1 (10) 0.008*
Ataxia 3 (25) 2 (50) NS† 4 (67) 1 (10) 0.04*
a NS, not significant. *, Compared to patients without these antibodies; †, compared to patients without these symptoms.
TABLE 4. Reactivity of toxins, lectin, and MAbs to purified gangliosides and LPSs from C. jejuni serostrains
Toxin, lectin, or
MAb
Reactivitya of:
Ganglioside LPS
GA1 GM1 GM2 GM3 GD1a GD1b GT1b GD3 GQ1b Pen O:3 Pen O:10 Pen O:19
CT biotin            
CT peroxidase            
PNA-peroxidase            
TT-peroxidase            
MAb Sm1            
MAb Wo1            
MAb Ha1rbc            
MAb EG1            
MAb CGM3            
a , No binding; , weak binding; , moderate binding; , strong binding.
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CT and the GM1 panel may recognize GM1-like immunore-
active epitopes on C. jejuni LPS and not necessarily an exact
structural mimic of the GM1 oligosaccharide. Furthermore,
our results indicate that approaches with the serum panel,
toxins and lectins, and monoclonal antibodies all have their
advantages and drawbacks. The observed good correlation be-
tween the three methods lead us to conclude that all three
methods can be used to define “GM1-like” and “GQ1b-like”
epitopes.
In conclusion, our data provide strong support for the hy-
pothesis that molecular mimicry between C. jejuni LPS and
gangliosides plays a key role in the induction of antiganglioside
antibodies and neurological symptomes in patients with GBS
or MFS. Furthermore, we have demonstrated that heteroge-
neity in the LPS structure determines the specificity of the
antiglycolipid response and thereby the clinical features in
patients with a post-Campylobacter neuropathy. The develop-
ment of serological assays for the determination of ganglioside
mimicry in C. jejuni LPS may be of great help in determining
genetic markers for potentially neuropathic strains (27).
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